Chaitali Gadade*
Herpes zoster (HZ), a well-known viral disease, usually presents as a painful unilateral vesicular rash that is restricted to the distribution of a sensory nerve. HZ, often known as shingles, is an acute viral infection caused by the reactivation of the DNA virus varicella zoster, which causes chickenpox. It typically manifests as an uncomfortable vesicular rash that takes four to five weeks to appear. The agony may last for months or even years after the skin lesions have healed. This condition is known as postherpetic neuralgia (PHN). Ten to eighteen percent of zoster patients are susceptible to PHN. Nearly 3% of zoster patients are admitted to hospitals. Zoster-related morbidity is common in patients with compromised immune systems. HZ can affect any one of the three branches of the trigeminal nerve. It is a somewhat rare incidence as just 1.7% of all HZ cases involve the mandibular and maxillary branches without ocular branch involvement. [1] PubMed and Google Scholar were used to search the literature for relevant published publications on HZ. Clinical trials, clinical investigations, review articles, systematic reviews, meta-analyses, case series, and case reports were all taken into account. "Varicella-zoster virus," "Herpes zoster," "treatment AND Herpes zoster," and "prevention AND Herpes zoster" were the keywords used to search the papers. [2]
Epidemiology of Herpes Zoster
The occurrence of HZ is worldwide and does not vary seasonally. The incidence of HZ is age-dependent, ranging from 1.2 to 3.4 per 1000 people per year in younger individuals to 3.9 to 11.8 per 1000 people per year in older patients (i.e., those over 65). The cumulative incidence, with a female predominance, has been estimated to be between 2.9 and 19.5 cases per 1000 people, according to a comprehensive review of research done between 2002 and 2018. Common risk factors for HZ include immunosuppression, infections, mental stress, and age over 50. A meta-analysis of 16 research published up until January 2021 found that patients with diabetes mellitus are also more vulnerable (pooled relative risk: 1.38; 95% CI: 1.21–1.57). A recent Indian study published in 2021 found a substantial correlation between pediatric HZ and megaloblastic anemia. Folic acid or vitamin B12 deficiency is the main cause of megaloblastic anaemia. The Global Burden of Disease database shows that the death rate from HZ for people over 65 ranges from 0.0022 to 82.21 per 100,000 population. The annual fatality rate of HZ has been determined to be 0.29 for women and 0.10 for males per 100,000 patient years based on German outpatient incidence data from 2007 and 2008. [3] It is important to take note of any potential heterogeneity in epidemiological data brought on by differences in reporting. The population of nations lacking efficient reporting systems may be smaller than that of nations with such systems. [4
10.5281/zenodo.17573446